Tilson L, McGowan B, Ryan M, Barry M
National Centre for Pharmacoeconomics, St. James's Hospital, James's Street, Dublin 8.
Ir Med J. 2003 Jun;96(6):176-9.
Expenditure on medicines under the Community Drug Schemes was Euro 674.8 million in 2001, a 27% increase as compared with the year 2000. Prescribing less expensive generic drugs is one method of reducing costs whilst maintaining therapeutic efficacy. In this study the cost and quantity of generic drugs dispensed and the potential savings for GMS prescribing in 2001 that could be made by increasing utilisation of generic drugs was investigated. Twenty two per cent of prescription items were dispensed generically (branded generics (17%) and non-branded generics (5%)) in 2001. This represented approximately 13% of the total ingredient cost of drugs dispensed in that period. Eighteen per cent of prescription items were dispensed as proprietary preparations when a generic equivalent was available. Eleven of the top 30 drugs, of highest cost to the GMS scheme, had a generic equivalent which if substituted could produce savings in the region of Euro 5.65 million. The results of this study highlight the potential for cost savings to be made by generic substitution, facilitating the most efficient use of the limited drugs budget.
2001年,社区药品计划下的药品支出为6.748亿欧元,与2000年相比增长了27%。开处方使用较便宜的非专利药是在保持治疗效果的同时降低成本的一种方法。在本研究中,调查了2001年发放的非专利药的成本和数量,以及通过提高非专利药的使用率可为全科医疗服务(GMS)开处方节省的潜在费用。2001年,22%的处方药是以非专利药形式发放的(品牌非专利药占17%,无品牌非专利药占5%)。这约占该时期发放药品总成分成本的13%。当有非专利等效药品时,18%的处方药是以专利制剂形式发放的。对全科医疗服务计划成本最高的30种药品中的11种,有非专利等效药品,若进行替换,可节省约565万欧元。本研究结果突出了通过非专利药替换实现成本节约的潜力,有助于最有效地利用有限的药品预算。